Search filters
Filters
Clear AllPhase
-
183
-
156
-
2
-
194
-
1
-
152
-
17
-
402
Age
-
1246
-
593
Gender
-
29
-
49
-
3
-
1172
Virtual Trials
-
1247
-
6
New Trials
-
4
-
1249
Loading...
Found 1253 All Conditions trials
A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
UPCC 39418: A Phase II Single Arm Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) In Adult Patients with Refractory or Relapsed Follicular Lymphoma
To evaluate the efficacy of tisagenlecleucel therapy among adult patients with refractory or relapsed follicular lymphoma as measured by complete response rate determined by Independent Review Committee in the full analysis set based on Lugano 2014 classification response criteria.
UPCC 30818: A Phase 2 Open-Label Single-Arm Multicenter Study to Assess the Safety and Efficacy of ASP1650 a Monoclonal Antibody Targeting Claudin 6 (CLDN6) in Male Subjects with Incurable Platinum Refractory Germ Cell Tumors
The goal of this study is to confirm that an investigational study drug, ASP1650, is both safe and effective as a treatment in participants with incurable, refractory germ cell tumors that have Claudin 6 (CLDN6) expression.
UPCC 54417: Phase I/II study of pembrolizumab in patients with relapsed or refractory extranodal NK/T cell lymphoma (ENKTL) nasal type and EBV-associated diffuse large B cell lymphomas (EBV-DLBCL)
The purpose of this study is to determine the safety and tolerability of pembrolizumab in people with lymphoma whose lymphoma relapsed or did not respond after receiving at least one prior treatment for lymphoma. This study will also determine how well patients with lymphoma respond to pembrolizumab.
Immunologic Analysis of Thoracic Duct Lymph from MS Patients and Controls
This study aims to investigate the benefits of collecting lymph in addition to blood in patients with multiple sclerosis (MS). It is now well recognized that the central nervous system (CNS) is not as immune privileged as it has been considered. A system of lymphatic drainage has been described both …
Recovery-Oriented Cognitive Therapy for Families
The purpose of this study is to evaluate the therapeutic benefit for participants receiving Recovery-Oriented Cognitive Therapy (CT-R) for families- a cognitive therapy based group for family members of individuals in the early stages of psychosis. A CT-R based intervention has shown to be effective for individuals with psychosis, offers …
UPCC 35218: Phase II Trial of Abemaciclib and Nivolumab for Subjects with Hepatocellular Carcinoma
The main purpose of this study is to evaluate the effectiveness of the combination of nivolumab and abemaciclib for the treatment of hepatocellular carcinoma. Other goals of this study are to learn about the side effects that this combination of drugs may cause and to learn more about how these …
UPCC 03418: A Phase 1 First in Human Open Label Dose Escalation Study of AMV564 a CD33 x CD3 Tandem Diabody in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Amphivena Therapeutics, Inc. (Amphivena) is studying an investigational drug called AMV564, which may help to treat acute myeloid leukemia (AML). The purpose of this clinical research study is to find the highest tolerable dose that can be given to patients with AML, and to recommend a dose to be used …
A Phase 2 Multicenter Open-Label Extension Study to Evaluate the Safety and Tolerability of AK002 in Patients with Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody to the inhibitory receptor Siglec-8, present on mast cells, eosinophils, and basophils. Binding of AK002 to Siglec-8 induces a signal that inhibits mast cell activation and can lead to apoptosis in eosinophils. In the presence of effector cells (such as …
UPCC 17518: A Phase 1 First-in-Human Open-Label Dose Escalation Study of MGD013 A Bispecific DART Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms
The primary objective of this study is to characterize the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of MGD013 when administered intravenously (IV) every 2 weeks to patients with unresectable, locally advanced or metastatic cancers.
Suicide and Trauma in Persons living with HIV
Rates of posttraumatic stress disorder (PTSD), substance use, sleep disorders and suicide are disproportionately higher in persons living with HIV (PLWH). The Syndemic Model of Substance Abuse, Intimate Partner Violence, and HIV (SAVA Syndemic), refers to the frequent co-occurrence and mutual influence between these conditions. The SAVA Syndemic has not …
Please choose between Voice or SMS based delivery of verification code
or